Bristol Myers Squibb (BMY) Change in Acquisitions & Divestments (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Change in Acquisitions & Divestments for 18 consecutive years, with $573.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 9.35% year-over-year to $573.0 million in Q2 2026; TTM through Jun 2026 was $2.2 billion, a 110.25% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 76.02% from the prior year.
• Change in Acquisitions & Divestments was $573.0 million for Q2 2026 at Bristol Myers Squibb, up from $391.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $2.1 billion in Q1 2022 and troughed at $41.0 million in Q4 2023.
• A 5-year average of $622.5 million and a median of $396.5 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments slumped 97.05% in 2023 and surged 1104.84% in 2024, its largest moves.
• Over 5 years, Change in Acquisitions & Divestments stood at $1.2 billion in 2022, then slumped by 96.6% to $41.0 million in 2023, then soared by 51.22% to $62.0 million in 2024, then jumped by 548.39% to $402.0 million in 2025, then surged by 42.54% to $573.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $573.0 million (Q2 2026), $391.0 million (Q1 2026), and $402.0 million (Q4 2025), per Business Quant data.